Temporal trends in lipoprotein(a) testing among United States veterans from 2014 to 2023
Despite a 9-fold increase in Lp(a) testing among US Veterans over the last decade, the overall testing rate remains extremely low. The steady proportion of Veterans with elevated Lp(a) over time supports the clinical utility of testing expansion. Efforts to increase testing, especially among Veterans living in neighborhoods with high social vulnerability, will be important to reduce emerging disparities as novel therapeutics to target Lp(a) become available.
Authors
- Tania Chen (ORCID: https://orcid.org/0000-0003-4095-1049)
- Natasha Din (ORCID: https://orcid.org/0000-0001-5312-4451)
- Fátima Rodríguez (ORCID: https://orcid.org/0000-0002-5226-0723)
- Paul A. Heidenreich (ORCID: https://orcid.org/0000-0001-7730-8490)
- Neil Kalwani (ORCID: https://orcid.org/0000-0003-0075-6206)
- Sofia Gomez (ORCID: https://orcid.org/0000-0002-0900-6519)
- David J. Maron (ORCID: https://orcid.org/0000-0002-4867-8588)
- Shriram Nallamshetty (ORCID: https://orcid.org/0000-0002-1256-5741)
- Alexander T. Sandhu (ORCID: https://orcid.org/0000-0003-3208-1143)
- Adam Furst (ORCID: https://orcid.org/0000-0002-4034-5623)
- Anthony Lozama
- Jonathan H Ward
Institutions
- Novartis (Switzerland) (CH)
- VA Palo Alto Health Care System (US)
- Palo Alto Veterans Institute for Research (US)
- Stanford Health Care (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1016/j.ajpc.2024.100872
- Citations
- 6
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 3.44
Funders
- American Heart Association
- Novartis Pharmaceuticals Corporation
- Arrowhead Pharmaceuticals
- Esperion Therapeutics
- National Heart, Lung, and Blood Institute